

DRAFT

Attorney Docket No: 23546-07666US
Client Ref: RTS-0297
USSN: 09/920,671

AMENDMENTS TO THE CLAIMS

1. (cancelled):
2. (cancelled):
3. (CURRENTLY AMENDED): A compound 20 to 50 ~~8 to 50~~ nucleobases in length targeted to a nucleic acid molecule encoding CoREST (SEQ ID NO:11), wherein said compound specifically hybridizes with said nucleic acid molecule encoding CoREST (SEQ ID NO:11) and inhibits the expression of CoREST, wherein said compound is an antisense oligonucleotide and has a sequence comprising SEQ ID NO:80.
4. (previously presented): The compound of claim 3 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
5. (Original): The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.
6. (previously presented): The compound of claim 3 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
7. (Original): The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
8. (previously presented): The compound of claim 3 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
9. (Original): The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.
10. (previously presented): The compound of claim 3 wherein the antisense oligonucleotide is a chimeric oligonucleotide.
11. (CURRENTLY AMENDED): ^{antisense} A compound 20 to 50 ~~8 to 50~~ nucleobases in length which specifically hybridizes with ~~at least an 8 nucleobase portion of~~ nucleobases 48225 to 48244 of a nucleic acid molecule encoding CoREST (SEQ ID NO:11), ^{and inhibits expression of} CoREST
12. (previously presented): A composition comprising the compound of claim 3 and a pharmaceutically acceptable carrier or diluent.

DRAFT

Attorney Docket No: 23546-07666US

Client Ref: RTS-0297

USPN: 09/920,671

13.(Original): The composition of claim 12 further comprising a colloidal dispersion system.

14. (canceled)

15. - 25 (Canceled)